Fifty-two elderly glaucomatous patients, without a history of asthma or obstructive airways disease, who were using topical timolol for control of intraocular pres sure were recruited. Their topical therapy was changed to either betaxolol or pilocarpine. The change was associ ated with improvement in mean peak flow from 278 I/min to 328 I/min (t = 5.73, p<O.OOl), mean FEV\ from 1.66 I to 1.85 I (t = 7.09,p<0.001) and mean FVC from 2.40 I to Glaucoma is a common disease in the elderly, affecting approximately 6% of those over 75 years,I-3 and topical therapy with the non-selective beta-adrenergic antagonist timolol is a common medical treatment. 4.5 Because of the convenient twice-daily dosage and the fact that it has few ocular side effects timolol is a popular drug with patients and ophthalmologists alike.
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Drugs administered topically to the eye gain direct access to the circulation by drainage through the naso lacrimal duct and absorption from the nasal mucosa. This avoids first pass metabolism by the liver. Significant amounts of timolol reach the circulation when it is admin istered topically to the eye6,7 and this is recognised to cause bronchospasm in patients with asthma8,9 or chronic obstructive airways disease,lo Topical timolol therapy is considered safe in patients without such a history. 
MATERIALS AND METHODS
To provide a group unaffected by beta-antagonists whose intraocular pressure was nevertheless controlled, a group of patients was changed to the cholinergic agent pilo carpine. Substitution of timolol by the more cardioselec tive betaxolol was used to ascertain whether other patients given a relatively cardioselective beta-antagonist would improve their lung function tests. patients using both timolol and pilocarpine who were given betaxolol. The controls were likewise assessed but no change was made to their topical medication.
Lung function tests were repeated after a 4-week period on the new therapy, the observer being unaware of the results of the subject's enrolment lung function tests. For statistical analysis independent t-tests were used to test significance of differences between the group changes in mean peak flow, FEV!, FVC and FEV/FVC between enrolment and review. Paired sample t-tests were used to P. DIGGORY ET AL. 
RESULTS
Fifty-two patients were enrolled in the study. Twenty seven were changed to betaxolol and 25 to pilocarpine. (Table III) .
Betaxolol therapy was associated with fewer ocular side effects than pilocarpine. Almost all of the 21 using pilo- There was no significant difference in mean values of lung function tests between the two drug groups. (Table IV) .
No patient required additional topical therapy as a result of stopping timolol. In the pilocarpine group there was a small, but statistically significant, fall in mean intraocular pressure (Table V) .
DISCUSSION
The majority of patients with glaucoma are elderly. They have a high prevalence of unrecognised bronchospasm. The improvement in lung function tests was seen in both the betaxolol and pilocarpine groups and there was no increase in mean intraocular pressure in either group.
We believe the extent of unrecognised impairment of lung function tests induced by topical timolol is too high to justify using it in the elderly unless lung function tests are performed before and after starting treatment. Pilocarpine therapy is effective in controlling intraocular pressure but it has a high incidence of local side effects, and potential systemic adverse reactions include confusion. I? This, and its four times daily administration, is likely to result in poor compliance in the elderly. If medical therapy with topical beta-antagonists is deemed essential we recom mend a cardioselective agent be chosen.
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